Answers are grounded in this paper and cite their sources.
Sir, We thank Tsai et al. (2017) for their interesting study presenting the first group of clinical cases with genetic and functional analysis of the human cytoplasmic tryptophanyl-tRNA synthetase (TrpRS) gene (WARS) (OMIM 191050). WARS has been proposed as a new cause of distal hereditary motor neuropathy (dHMN). The authors first identified a heterozygous mutation, c.770A>G (p.His257Arg), in a three-generation Taiwanese family originating from the Han nationality. In this family, four members were affected with autosomal dominant dHMN. The same mutation was identified in another Taiwanese dHMN family with different ancestry and an additional Belgian dHMN pedigree of Caucasian origin (Tsai et al., 2017). Aminoacyl-tRNA synthetases (ARSs) are essential enzymes responsible for charging amino acids to cognate tRNA molecules, which is the prerequisite step for translating mRNA to protein (Sissler et al., 2017). The recent research findings indicate that pathogenic mutations of cytosolic ARSs are relevant to neuropathies of the peripheral nervous system and mutations of the mitochondrial ARSs are relevant to encephalopathies (Ognjenović and Simonović, 2017). As a member of ARSs, human TrpRS encoded by the WARS gene is an essential enzyme responsible for charging tRNAtrp molecules with tryptophan. The human TrpRS protein (471 amino acids) contains an N-terminal domain (residues 1–154), a Rossmann fold catalytic domain (residues 155–353) and a C-terminal anticodon binding domain (residues 354–471) (Xu et al., 2017). Here, we would like to report a novel missense mutation c.413T>A (p.Phe138Tyr) in exon 4 of WARS (RefSeq NM_004184.3) in a Han Chinese family with dHMN identified by using whole exome sequencing (WES). Written informed consents for the genetic research were obtained from all the participants. The study was approved by the ethics board of the Department of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine. In this family, the proband is a 35-year-old male with a history of progressive weakness and muscle atrophy of the lower limbs for 25 years. The slowly progressive distal muscle weakness began in his feet and ankles, followed by weakness in the intrinsic muscles of his hands. He was beset with foot drop and clumsy hands while growing up. The patient now has difficulty with long-distance walking. No one else in his family has ever had a similar experience. Neuromuscular examinations at the age of 29 showed distal muscle atrophy at four limbs, weak deep tendon reflexes and neither subjective superficial nor deep sensory dysfunction. In electrophysiological studies, the median motor nerve conduction velocities (MNCVs) in the patient’s right and left upper limb were 47.9 m/s and 35.5 m/s, respectively. The ulnar nerve compound motor action potentials (CMAPs) in his right and left upper limb were 1.2 mV and 0.1 mV, respectively, and the ulnar nerve sensory nerve action potentials (SNAPs) were 39 μV and 57 μV, respectively. These results showed a pure axonal motor neuropathy and normal sensory nerve conduction of the upper and lower extremities, which was concordant with the clinical observations of the patient. After a negative MLPA analysis of the PMP22 gene, WES was performed in this patient. A heterozygous missense variant, c.413T>A (p.Phe138Tyr), in WARS was identified as the primary candidate mutation after verifying by Sanger sequencing. Family co-segregation analysis showed that the variant was only detected in the proband but not in the other familial members. We further confirmed the maternity and paternity by comparing their core STR regions (Fig. 1A and B). Therefore, the p.Phe138Tyr variant we reported is a de novo variant. It was absent from the ExAC, dbSNP, 1000G, gnomAD and our WES database that covers the WARS gene and contains 300 Chinese controls. The Phe138 residue is highly conserved throughout vertebrate species, suggesting that the mutation may be damaging (Fig. 1C). The amino acid is localized in the eukaryotic-specific extension, which is a part of the N-terminal extension folding into the eukaryote-specific patch (Yang et al., 2007) (Fig. 1D). It was predicted to be disease-causing by MutationTaster, SIFT, M-CAP and CADD. In silico CADD analysis of the missense WARS variant, a high score of 25.6 indicates that p.Phe138Tyr is in the top 1% most deleterious variants in the genome (Kircher et al., 2014). Genetic and functional analysis of the Chinese family with distal hereditary motor neuropathy (dHMN). (A) The pedigree shows segregation of c.413T>A (p.Phe138Tyr) within WARS that has been confirmed. The analysis of the repeat numbers of 16 core STR loci in the three participants showed the probability of the patient being the alleged parents’ biological son was calculated as 99.99%. Circle = female; square = males; open symbol = unaffected; filled symbol = affected; arrow = proband. (B) The sequencing chromatogram of c.413T>A (p.Phe138Tyr) within WARS. The upper chromatogram represents the normal sequence and the lower one represents the mutant sequence. (C) Alignment analysis for the p.Phe138Tyr mutation for TrpRS orthologues in different species shows conservation of the Phe138 residue throughout vertebrate species (amino acid position 138 is boxed in red). (D) The domain diagram of human TrpRS shows the location of previously-reported His257 residue (above) and the Phe138 residue in the present study (below). ESE = eukaryotic-specific extension; VSE = vertebrate-specific extension. (E and F) Protein expression of wild-type (WT) and mutant WARS. HEK293T cells expressing p.Phe138Tyr showed lower protein level than those expressing wild-type WARS, while p.His257Arg did not affect the protein level. **P < 0.01. ns = non-significant. We then further explored the influence of p.Phe138Tyr mutation on the function of TrpRS. The pcDNA3.1/myc-His-WARS wild-type (WT) and pcDNA3.1/myc-His-WARS His257Arg expression plasmids were gifts from Tsai et al. The WARS mutation c.413T>A (p.Phe138Tyr) identified in this study was introduced into the pcDNA3.1/myc-His-WARS wild-type plasmid using PCR mutagenesis. We transfected these expression plasmids into human embryonic kidney 293T (HEK293T) cells. Interestingly, western blot analysis demonstrated that the expression level of the p.Phe138Tyr mutant WARS was noticeably lower than that of wild-type WARS (P < 0.01), whereas there was no significant difference between the wild-type and the p.His257Arg mutant WARS (P > 0.05) (Fig. 1E and F). According to the guidelines of the American College of Medical Genetics and Genomics (ACMG) (Richards et al., 2015), this variant was classified as a ‘pathogenic’ variant. To date, two missense WARS mutations including the one identified here have been described. The mutation p.His257Arg is localized in the catalytic domain, and the p.Phe138Tyr mutation that we identified is the first one that is localized in the eukaryotic-specific extension of the N-terminal domain. Previously, functional studies provided strong evidence for a loss-of-function effect of other disease-associated ARS mutations (Wallen and Antonellis, 2013). Tsai et al. (2017) found the mutation p.His257Arg had a dominant-negative effect on aminoacylation activity of TrpRS, inhibited neurite outgrowth and resulted in neurite degeneration in the neuronal cell lines and rat motor neurons. In this study, we proved that HEK293T cells expressing p.Phe138Tyr had a lower protein level than those expressing wild-type WARS while p.His257Arg did not affect the protein level. The decrease of its expression may lead to an adverse impact on the general level of the protein translation. It may be possible that the translational machinery is not able to meet the demand for highly metabolic protein synthesis in axons (Griffin et al., 2014). As a consequence, it suggests a sensible pathogenic mechanism of axonal peripheral neuropathy like dHMN. In summary, our study provides a novel WARS mutation in a Chinese family affected with dHMN, expanding the spectrum of causative mutations and further confirmed the pathogenicity of WARS mutations in dHMN. The authors confirm that the data supporting the findings of this study are available within the article and its Supplementary material. The URLs used in this study: Online Mendelian Inheritance in Man; https://www.omim.org/ The Exome Aggregation Consortium (ExAC); http://exac.broadinstitute.org/ The Single Nucleotide Polymorphism database (dbSNP); https://www.ncbi.nlm.nih.gov/snp 1000 Genomes Browser; http://www.internationalgenome.org/1000-genomes-browsers/ Genome Aggregation Database (gnomAD); http://gnomad.broadinstitute.org/ Mutation Taster; http://www.mutationtaster.org/ SIFT; http://sift.jcvi.org/ Mendelian Clinically Applicable Pathogenicity (M-CAP); http://bejerano.stanford.edu/MCAP/ Combined Annotation Dependent Depletion (CADD); http://cadd.gs.washington.edu/home We would like to thank the patient and his family members for participating in this study. We appreciate Prof. Yi-Chung Lee and his team for their great help providing pcDNA3.1/myc-His-WARS WT and pcDNA3.1/myc-His-WARS His257Arg plasmids. This study was supported by the research foundation for distinguished scholar of Zhejiang University to Zhi-Ying Wu (188020–1938 10101/089) and the Fundamental Research Funds for the Central Universities (2019XZZX001–01–04). The authors report no competing interests.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: